文章摘要
程秀俊,唐海沁.替格瑞洛在急性冠脉综合征患者治疗中的疗效和安全性评价[J].中国临床保健杂志,2019,22(2):237-240.
替格瑞洛在急性冠脉综合征患者治疗中的疗效和安全性评价
To evaluate the efficacy and safety of ticagrelor in the treatment of patients with acute coronary syndrome
投稿时间:2018-12-02  
DOI:10.3969/J.issn.1672-6790.2019.02.024
中文关键词: 急性冠状动脉综合征  血小板聚集抑制剂  治疗结果  病人安全  Meta分析
英文关键词: Acute Coronary Syndrome  Platelet aggregation inhibitors  Treatment outcome  Patient safety  Meta-analysis 〖FL
基金项目:国家中医药管理局国家中医临床研究基地业务建设科研专项课题(JDZX2015133)
作者单位E-mail
程秀俊 安徽医科大学第一附属医院全科医学科,合肥 230022 tanghq898@sina.com 
唐海沁 安徽医科大学第一附属医院全科医学科,合肥 230022 tanghq898@sina.com 
摘要点击次数: 455
全文下载次数: 389
中文摘要:
      目的 以氯吡格雷为对照,评估替格瑞洛在急性冠脉综合征(ACS)患者治疗方案中的疗效和安全性。 方法 使用计算机检索国内外数据库自建库至2018年7月公开发表的关于应用替格瑞洛治疗急性冠脉综合征患者的RCTs研究文献,依据Cochrane Reviewer's Handbook中的RCT质量评价标准进行质量评价后,对入选文献进行资料提取,并使用RevMAN5.3软件进行MATE分析。 结果 共纳入10项RCTs研究,共34 416名患者。①替格瑞洛对比氯吡格雷可以明显减少主要心血管事件(MACE)的发生(OR=0.71,95%CI:0.60~0.83,P<0.001)。②替格瑞洛对比氯吡格雷出血风险无明显差别(OR=1.08,95%CI为1.01~1.15,P<0.05)。③替格瑞洛对比氯吡格雷增加呼吸困难事件的发生(OR=1.86,95%CI:1.70~2.04,P<0.001)。 结论替格瑞洛组患者MACE发生率明显降低,且降低了出血风险,但存在较高的呼吸困难发生率。
英文摘要:
      Objective To evaluate the efficacy and safety of ticagrelor in the treatment of patients with acute coronary syndrome (ACS) with clopidogrel as control. Method The database from domestic and foreign were retrieved with computer for collecting the RCTs research literature on the treatment of patients with acute coronary syndrome from the datebase establishment to July 2018.Quality evaluation were performed according to the standard for RCT quality evaluation standard(set by Cochrane Reviewer's Handbook) ,and the date were extracted from selected literatures and given a Meta-analysis by using RevMen5.1 software. Results From a total of 10 RCTs studies 34416 patients were included.①Ticagrelor reduced the incidence of MACE events significantly(OR=0.71,95%CI of 0.60-0.83,P<0.0001).②In the incidence of bleeding events,Ticagrelor was not different from clopidogrel (OR=1.08,95%CI of 1.01-1.15,P<0.05).③Ticagrelor increased the incidence of dyspnea events(OR=1.86,95%CI of 1.70-2.04,P<0.00001). Conclusion The incidence of MACE in the Ticagrelor group was significantly reduced,and the risk of bleeding was reduced,but there was a higher incidence of dyspnea.
查看全文     下载PDF阅读器
关闭
分享按钮